Clinical Trial Update: Efficacy of SEROQUEL in Selective Serotonin Reuptake Inhibitors (SSRI)-Resistant Major Depressive Disorder [Phase 2]

View source ↗

Summary

Phase 2 trial examining the efficacy of SEROQUEL (quetiapine) as an adjunct to SSRI therapy in patients with SSRI-resistant major depressive disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• SEROQUEL (QUETIAPINE)

Snippet

Sponsor: AstraZeneca | Conditions: Major Depressive Disorder | Phase 2 | Status: COMPLETED